Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCR NASDAQ:IMVT NASDAQ:SYRE NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$29.55+2.5%$30.98$27.44▼$40.71$1.50B0.74429,534 shs420 shsIMVTImmunovant$27.91+0.3%$26.11$13.36▼$30.09$5.70B0.71.42 million shs1,007 shsSYRESpyre Therapeutics$70.79-0.3%$52.30$12.28▼$76.00$5.58B3.12925,592 shs2,397 shsTGTXTG Therapeutics$40.56+12.4%$32.24$25.28▼$40.99$5.89B1.682.01 million shs117,053 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore+2.41%+0.17%-6.45%-8.44%-5.84%IMVTImmunovant+2.65%+3.15%+13.63%+10.70%+82.92%SYRESpyre Therapeutics+2.29%+3.47%+49.24%+121.42%+403.97%TGTXTG Therapeutics+6.70%+4.40%+7.66%+23.97%-4.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$29.55+2.5%$30.98$27.44▼$40.71$1.50B0.74429,534 shs420 shsIMVTImmunovant$27.91+0.3%$26.11$13.36▼$30.09$5.70B0.71.42 million shs1,007 shsSYRESpyre Therapeutics$70.79-0.3%$52.30$12.28▼$76.00$5.58B3.12925,592 shs2,397 shsTGTXTG Therapeutics$40.56+12.4%$32.24$25.28▼$40.99$5.89B1.682.01 million shs117,053 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore+2.41%+0.17%-6.45%-8.44%-5.84%IMVTImmunovant+2.65%+3.15%+13.63%+10.70%+82.92%SYRESpyre Therapeutics+2.29%+3.47%+49.24%+121.42%+403.97%TGTXTG Therapeutics+6.70%+4.40%+7.66%+23.97%-4.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.36Hold$60.89106.05% UpsideIMVTImmunovant 2.45Hold$32.4416.25% UpsideSYRESpyre Therapeutics 3.00Buy$85.0820.19% UpsideTGTXTG Therapeutics 2.57Moderate Buy$50.0023.27% UpsideCurrent Analyst Ratings BreakdownLatest IMCR, SYRE, TGTX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026TGTXTG Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/27/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026IMCRImmunocore Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026IMCRImmunocore HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/17/2026SYRESpyre Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$64.00 ➝ $95.004/15/2026IMVTImmunovant The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$29.00 ➝ $32.004/14/2026SYRESpyre Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $90.004/14/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $88.004/14/2026IMCRImmunocore HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/14/2026SYRESpyre Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$65.00 ➝ $90.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$400.02M3.74N/AN/A$7.52 per share3.93IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ASYRESpyre Therapeutics$890K6,266.37N/AN/A$7.21 per share9.82TGTXTG Therapeutics$616.29M10.08$3.18 per share12.74$4.08 per share9.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$35.51M-$0.70N/AN/AN/A-8.88%-9.20%-3.32%5/6/2026 (Estimated)IMVTImmunovant-$413.84M-$2.69N/AN/AN/AN/A-63.17%-58.01%6/4/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-41.79%-25.97%5/14/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.7713.8816.56N/A72.56%101.12%51.88%5/6/2026 (Estimated)Latest IMCR, SYRE, TGTX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SYRESpyre Therapeutics-$0.66N/AN/AN/A$70.87 millionN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.03 million$106.68 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.17-$0.06$0.12$200.33 millionN/A5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 million2/25/2026Q4 2025IMCRImmunocore-$0.28-$0.60-$0.32-$0.60$145.48 million$104.48 million2/19/2026Q4 2025SYRESpyre Therapeutics-$0.66-$0.70-$0.04-$0.70N/AN/A2/14/2026Q4 2025IMCRImmunocoreN/A-$0.60N/A-$0.60N/A$104.48 million2/6/2026Q3 2026IMVTImmunovant-$0.72-$0.61+$0.11-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.034.044.01IMVTImmunovantN/A15.7415.74SYRESpyre TherapeuticsN/A13.2513.25TGTXTG Therapeutics0.384.103.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%IMVTImmunovant47.08%SYRESpyre Therapeutics80.39%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%IMVTImmunovant1.80%SYRESpyre Therapeutics15.69%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.69 million45.42 millionOptionableIMVTImmunovant120203.53 million199.87 millionOptionableSYRESpyre Therapeutics7378.78 million66.42 millionOptionableTGTXTG Therapeutics290153.09 million142.70 millionOptionableIMCR, SYRE, TGTX, and IMVT HeadlinesRecent News About These CompaniesTG Therapeutics (TGTX) Q1 Earnings Lag Estimates17 minutes ago | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTX1 hour ago | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance2 hours ago | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by AnalystsApril 30, 2026 | marketbeat.comFortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthApril 28, 2026 | zacks.comTG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comTG Therapeutics (TGTX) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comM&T Bank Corp Buys Shares of 125,789 TG Therapeutics, Inc. $TGTXApril 27, 2026 | marketbeat.comTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American ...April 22, 2026 | caledonianrecord.comCTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual MeetingApril 22, 2026 | finance.yahoo.comQ1 EPS Estimates for TG Therapeutics Cut by HC WainwrightApril 22, 2026 | marketbeat.comHC Wainwright Forecasts Lower Earnings for TG TherapeuticsApril 21, 2026 | marketbeat.comA Look At TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumApril 19, 2026 | finance.yahoo.comTG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster OutlookApril 18, 2026 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo FinanceApril 17, 2026 | finance.yahoo.comTGTX Completes Enrollment in Phase III Study on Subcutaneous BriumviApril 16, 2026 | zacks.comTG Therapeutics, Inc.: TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIApril 15, 2026 | finanznachrichten.deTG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVIApril 15, 2026 | globenewswire.comTG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting DownsideMarch 31, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMCR, SYRE, TGTX, and IMVT Company DescriptionsImmunocore NASDAQ:IMCR$29.55 +0.71 (+2.46%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Immunovant NASDAQ:IMVT$27.91 +0.07 (+0.25%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Spyre Therapeutics NASDAQ:SYRE$70.79 -0.22 (-0.31%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.TG Therapeutics NASDAQ:TGTX$40.56 +4.46 (+12.36%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
